WASHINGTON, D.C. and NORWELL, Mass. — In a unified display of advocacy and urgency, a coalition of patients, caregivers, medical clinicians, and leaders from the rare disease community converged on Capitol Hill to place a national spotlight on a staggering statistic: one in every four cancer patients in the United States is diagnosed with a rare form of the disease.
Organized by the National Organization for Rare Disorders (NORD®) Rare Cancer Coalition® (RCC), the advocacy day was designed to bring lawmakers face-to-face with the severe diagnostic hurdles, research deficits, and treatment roadblocks that define the rare cancer experience. Throughout a busy schedule of legislative meetings, participants issued a direct call to action, urging members of Congress to safeguard and expand essential federal investments, specifically targeting the National Cancer Institute (NCI) and the specialized Rare Cancers Research Program.
Rare cancers—a broad and devastating category that encompasses all pediatric cancers—present distinct, often overwhelming obstacles for patients and the medical professionals trying to save them. Because these malignancies involve small patient populations, they inherently suffer from limited clinical research, a scarcity of targeted treatment options, and profound barriers to obtaining a timely and accurate diagnosis.
Patients frequently endure long, frustrating diagnostic odysseys. They may see numerous physicians whose familiarity with the specific disease is limited, watch as their symptoms mimic more common and easily misunderstood conditions, and face agonizing delays in acquiring appropriate pathology or advanced molecular and biomarker testing.
Despite representing a full 25 percent of all cancer diagnoses and total cancer-related deaths in the United States, rare cancer research remains severely underfunded and understudied when compared to more common malignancies. This historical imbalance leaves countless families with few, if any, viable therapeutic avenues after receiving a life-altering diagnosis.
During their meetings with lawmakers, the delegation of rare cancer advocates zeroed in on a critical federal funding mechanism: an annual $17.5 million congressional earmark dedicated to the Rare Cancers Research Program, which is overseen by the Department of Defense Congressionally Directed Medical Research Program (CDMRP). Advocates emphasized that this funding stream is not merely a bureaucratic line item, but a vital lifeline capable of fueling clinically impactful discoveries and turning the tide for patients who have exhausted standard options.
The Capitol Hill delegation met with ten congressional offices representing key rare cancer patient and research constituencies across Colorado, Massachusetts, Maryland, Michigan, and Virginia. These meetings offered lawmakers an unfiltered look at the human cost of underfunding, as participants shared their personal and professional experiences with the disease and pressed for sustained federal investment.
Among the prominent participants leading the advocacy efforts were Michael Beard, NORD Vice President of Federal and Global Public Policy; a team of four expert clinicians from the Pediatric Cancer Genetics Clinic at Children’s National Hospital; and six key member organizations of the NORD Rare Care Coalition. The coalition leaders included Jim Palma, Chief Executive Officer of the TargetCancer Foundation; Kristen Palma, President of the TargetCancer Foundation; Jeffery Kramer, President of the Chondrosarcoma Foundation; Ben Wilson, Chair of Community Engagement for the Bloom Syndrome Association; Elizabeth Accad, Community Engagement Manager of the Cutaneous Lymphoma Foundation; and Janet Thompson, Executive Director of the VHL Alliance.
Pam Gavin, Chief Executive Officer of NORD, underscored the systemic frustrations that drive families to the halls of Congress.

“Too many families impacted by rare cancer endure a long path to diagnosis, often seeing multiple providers, struggling to find specialists with experience in their cancer and facing delays in specialized testing, only to discover that treatment options may be limited,” Gavin said. “I am proud of the NORD Rare Cancer Coalition advocates who brought their experiences to Capitol Hill today to urge Congress to increase funding for the National Cancer Institute and advance rare cancer research.”
For many participants, the push for increased research funding is deeply personal. Kristen Palma of Cambridge, Massachusetts, reflected on the profound isolation and helplessness that families faced years ago, contrasting it with the tangible progress generated by targeted federal grants today.
“Rare Cancer Day is a day to recognize a community of patients and families who are too often overlooked while acknowledging their unique challenges and needs. And it is a day to commit to action,” Palma said. “I remember how isolated, devastated and terrified we felt when we learned that my 38-year-old husband Paul’s cancer was rare and had no treatment options. Rare Cancer Day did not exist then, there was not a community for us to turn to, and dollars were not being spent to discover treatments for a cancer like his.”
Palma emphasized that the hard-fought progress of recent years must not be allowed to falter. “The discoveries made through grants supported by the Department of Defense CDMRP Rare Cancer Program are directly impacting patients today, giving time to families that we never had,” she added. “We have come so far since then and cannot let that momentum slow down, even for a moment.”
The momentum generated on Capitol Hill will carry directly into next month’s programming at NORD’s 2026 Rare Disease & Orphan Products Breakthrough Summit®. The upcoming conference is expected to draw more than 900 rare disease stakeholders to Washington, D.C., where they will convene to address shared systemic challenges in diagnosis, clinical research, drug development, and patient access to care—with a dedicated focus on the unique hurdles facing individuals living with rare cancers.
Formalized in 2017, the Rare Cancer Coalition operates as a specialized program under the NORD membership umbrella, uniting 30 distinct rare cancer-specific patient advocacy organizations. Together, the coalition works to improve health outcomes through coordinated awareness campaigns, research initiatives, educational outreach, and advocacy.
To further amplify these efforts, the coalition established Rare Cancer Day in 2019, creating an annual observance to rally the rare cancer community, elevate public awareness of the obstacles patients and families face, and accelerate progress toward earlier diagnoses and effective treatments. Beginning in 2026, Rare Cancer Day is officially recognized on September 23, marking a shift from its historical observance on September 30.
Founded in 1983, the National Organization for Rare Disorders remains the leading independent, nonpartisan, nonprofit organization dedicated to improving the health and well-being of the more than 30 million Americans living with rare diseases. By partnering with over 350 disease-specific member patient organizations, NORD continues to drive meaningful progress across the entire spectrum of rare disease research, clinical care, and federal policy.
